Lycia Therapeutics Raises $75 Million Series D To Advance LYTAC Pipeline
By Amit Chowdhry ● Jun 29, 2026
Lycia Therapeutics announced that it has completed an oversubscribed $75 million Series D financing. The financing was co-led by existing investor Janus Henderson Investors and new investor Balyasny Asset Management. The round also included new participation from Adage Capital Management, HBM Healthcare Investments, and OrbiMed, along with continued support from Eli Lilly and Company, Franklin Templeton, Invus, RTW Investments, and Venrock Healthcare Capital Partners.